FDA Approves Roche HPV Assay as First-Line Cervical Cancer Screening Method | GenomeWeb

NEW YORK (GenomeWeb) — Roche said today that the US Food and Drug Administration has approved its cobas HPV test for use as a first-line primary screening test for cervical cancer in women ages 25 years and older.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: parent-of-origin effects, framework to uncover clinically important mutations from whole genome sequence data, and more.

A survey of Cincinnati schoolchildren finds teenagers want to know their genetic predisposition to disease, LiveScience reports.

More and more universities are helping their researchers patent their inventions, the Los Angeles Times reports.

Cancer Research UK unveils seven 'grand challenges' that it will fund researchers to tackle.